FOXP1 and SPINK1 reflect the risk of cirrhosis progression to HCC with HBV infection

Biomedicine and Pharmacotherapy

Volumn 72, Issue , 2015, Pages 103-108

  Li, Fei ^a   Liu, Ting ^a   Xiao, Chun Yang ^a   Yu, Jing Xia ^a   Lu, Lun Gen ^a   Xu, Ming Yi ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Cirrhosis; Forkhead box protein 1 (FOXP1); Hepatitis B virus (HBV); Hepatocellular carcinoma (HCC); Serine protease inhibitor Kazal type 1 (SPINK1)

Indexed keywords

FORKHEAD BOX PROTEIN 1; FORKHEAD TRANSCRIPTION FACTOR; MESSENGER RNA; SERINE PROTEASE INHIBITOR KAZAL TYPE 1; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; CARRIER PROTEIN; FOXP1 PROTEIN, HUMAN; REPRESSOR PROTEIN; SPINK1 PROTEIN, HUMAN;

ADULT; ARTICLE; CANCER GROWTH; CANCER RISK; CLINICAL ARTICLE; DOWN REGULATION; FEMALE; HEPATITIS B; HUMAN; HUMAN TISSUE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER RESECTION; MALE; MARKER GENE; MICROARRAY ANALYSIS; MIDDLE AGED; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; DISEASE COURSE; DNA MICROARRAY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; HEPATITIS B VIRUS; LIVER TUMOR; METABOLISM; PATHOLOGY; PHYSIOLOGY; REAL TIME POLYMERASE CHAIN REACTION; RISK FACTOR; VIROLOGY;

ADULT; CARCINOMA, HEPATOCELLULAR; CARRIER PROTEINS; DISEASE PROGRESSION; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HEPATITIS B VIRUS; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; REAL-TIME POLYMERASE CHAIN REACTION; REPRESSOR PROTEINS; RISK FACTORS; UP-REGULATION;

EID: 84930520245     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2015.04.006     Document Type: Article

References (23)

1. Papatheodoridis G.V., Chan H.L., Hansen B.E., et al. Risk of hepatocellular carcinoma in chronic hepatitis B: assessment and modification with current antiviral therapy. J. Hepatol. 2015, 62(4):956-967.
2. Lok A.S., Seeff L.B., Morgan T.R., et al. Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gastroenterology 2009, 136(1):138-148.
3. Yang H., Sherman M., Su J., et al. Nomograms for risk of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. J. Clin. Oncol. 2010, 28(14):2437-2444.
4. Bruix J., Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011, 53(3):1020-1022.
5. Suzuki K., Okuda Y., Ota M., et al. Diagnosis of hepatocellular carcinoma nodules in patients with chronic liver disease using contrast-enhanced sonography: usefulness of the combination of arterial- and kupffer-phase enhancement patterns. J. Ultrasound Med. 2015, 34(3):423-433.
6. Altekruse S.F., Mcglynn K.A., Dickie L.A., et al. Hepatocellular carcinoma confirmation, treatment, and survival in surveillance, epidemiology, and end results registries, 1992-2008. Hepatology 2012, 55(2):476-482.
7. Rich N., Singal A.G. Hepatocellular carcinoma tumour markers: current role and expectations. Best Pract. Res. Clin. Gastroenterol. 2014, 28(5):843-853.
8. Schutte K., Schulz C., Link A., et al. Current biomarkers for hepatocellular carcinoma: Surveillance, diagnosis and prediction of prognosis. World J. Hepatol. 2015, 7(2):139-149.
9. Proceedings of a Bridge to a Consensus on Hepatocellular Carcinoma Management. The 2nd Asia Pacific Primary Liver Cancer Expert Meeting. Oncology 2011, 81(Suppl. 1):1-164.
10. Chinese Society of Liver Cancer, Chinese Anti-Cancer Association, Chinese Society of Clinical Oncology, et al. Expert consensus on the scheme of pathological diagnosis of primary liver cancer. Zhonghua Gan Zang Bing Za Zhi 2011, 19(4):254-256. (in Chinese).
11. Scheuer P.J. The nomenclature of chronic hepatitis: time for a change. J. Hepatol. 1995, 22:112-114.
12. Scheuer P.J. Classification of chronic viral hepatitis: a need for reassessment. J. Hepatol. 1991, 13:372-374.
13. Bullinger L., Dohner K., Bair E., et al. Use of gene expression profiling to identify prognostic subclasses in adult acute myeloid leukemia. N. Engl. J. Med. 2004, 350(16):1605-1616.
14. Tibshirani R., Hastie T., Narasimhan B., et al. Diagnosis of multiple cancer types by shrunken centroids of gene expression. Proc. Natl. Acad. Sci. U.S.A. 2002, 99(10):6567-6572.
15. Budhu A., Wang X.W. The role of cytokines in hepatocellular carcinoma. J. Leukoc. Biol. 2006, 80(6):1197-1213.
16. Yang J.D., Kim W.R., Coelho R., et al. Cirrhosis is present in most patients with hepatitis B and hepatocellular carcinoma. Clin. Gastroenterol. Hepatol. 2011, 9(1):64-70.
17. Green M.R., Gandhi M.K., Courtney M.J., et al. Relative abundance of full-length and truncated FOXP1 isoforms is associated with differential NFkappaB activity in Follicular Lymphoma. Leuk. Res. 2009, 33(12):1699-1702.
18. Bates G.J., Fox S.B., Han C., et al. Expression of the forkhead transcription factor FOXP1 is associated with that of estrogen receptor-beta in primary invasive breast carcinomas. Breast Cancer Res. Treat. 2008, 111(3):453-459.
19. Hotakainen K., Bjartell A., Sankila A., et al. Differential expression of trypsinogen and tumor-associated trypsin inhibitor (TATI) in bladder cancer. Int. J. Oncol. 2006, 28(1):95-101.
20. Lee Y.C., Pan H.W., Peng S.Y., et al. Overexpression of tumour-associated trypsin inhibitor (TATI) enhances tumour growth and is associated with portal vein invasion, early recurrence and a stage-independent prognostic factor of hepatocellular carcinoma. Eur. J. Cancer 2007, 43(4):736-744.
21. Ateeq B., Tomlins S.A.B., et al. Therapeutic targeting of SPINK1-positive prostate cancer. Sci. Transl. Med. 2011, 3(72):72ra17.
22. Gaber A., Nodin B., Hotakainen K., et al. Increased serum levels of tumour-associated trypsin inhibitor independently predict a poor prognosis in colorectal cancer patients. BMC Cancer 2010, 10:498.
23. Gaber A., Johansson M., Stenman U.H., et al. High expression of tumour-associated trypsin inhibitor correlates with liver metastasis and poor prognosis in colorectal cancer. Br. J. Cancer 2009, 100(10):1540-1548.